Display options
Cite
Anagnostou O, Manolakopoulos S, Bakoyannis G, et al. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Hippokratia. 2014;18(1):57-64
Anagnostou, O., Manolakopoulos, S., Bakoyannis, G., Papatheodoridis, G., Zisouli, A., Raptopoulou-Gigi, M., Manesis, E., Ketikoglou, I., Dalekos, G., Gogos, C., Vassiliadis, T., Tzourmakliotis, D., Karatapanis, S., Kanatakis, S., Zoumpoulis, -., Hounta, A., Koutsounas, S., Giannoulis, G., Tassopoulos, N., & Touloumi, G. (2014). Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Hippokratia, 18(1), 57-64.
Anagnostou, O, et al. "Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study." Hippokratia vol. 18,1 (2014): 57-64.
Anagnostou O, Manolakopoulos S, Bakoyannis G, Papatheodoridis G, Zisouli A, Raptopoulou-Gigi M, Manesis E, Ketikoglou I, Dalekos G, Gogos C, Vassiliadis T, Tzourmakliotis D, Karatapanis S, Kanatakis S, Zoumpoulis -, Hounta A, Koutsounas S, Giannoulis G, Tassopoulos N, Touloumi G. Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study. Hippokratia. 2014 Jan;18(1):57-64. PMID: 25125954; PMCID: PMC4103044.
Copy Download .nbib Format: NLM
Share it on

Hippokratia. 2014 Jan;18(1):57-64.

Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.

Hippokratia

O Anagnostou, S Manolakopoulos, G Bakoyannis, G Papatheodoridis, A Zisouli, M Raptopoulou-Gigi, E Manesis, I Ketikoglou, G Dalekos, C Gogos, T Vassiliadis, D Tzourmakliotis, S Karatapanis, S Kanatakis, - Zoumpoulis, A Hounta, S Koutsounas, G Giannoulis, N Tassopoulos, G Touloumi

Affiliations

  1. Department of Hygiene, Epidemiology & Medical Statistics, Athens University Medical School, Athens, Greece.
  2. 2 Academic Department of Medicine, Hippokration General Hospital, Athens, Greece.
  3. Office of Viral Hepatitis, Hellenic Center for Disease Control and Prevention, Athens, Greece.
  4. 2nd Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  5. Division of Internal Medicine, Athens University Medical School, Athens, Greece.
  6. State Department of Internal Medicine, Hippokration General Hospital, Athens, Greece.
  7. Department of Medicine and Research Laboratory of Internal Medicine, School of Medicine, University of Thessaly, Larissa, Greece.
  8. 1 Department of Internal Medicine, University of Patras, Medical School, Rio, Greece.
  9. 1 Propaedeutic Clinic of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  10. Department of Gastroenterology, Polyclinic General Hospital, Athens, Greece.
  11. Department of Internal Medicine, General Hospital of Rhodos, Rhodos, Greece.
  12. 1 Department of Internal Medicine, Red Cross Hospital, Athens, Greece.
  13. 1 Department of Propaedeutic Medicine, Athens University Medical School, ''Laiko'' Hospital, Athens, Greece.
  14. 4 Department of Internal Medicine, General University Hospital "Attikon", Athens, Greece.
  15. Hepatology Service, Foundation of Social Insurance (IKA), Athens, Greece.
  16. 2 Department of Internal Medicine, Tzaneio Hospital, Athens, Greece.
  17. 1 Department of Internal Medicine, Western Attica General Hospital, Athens, Greece.

PMID: 25125954 PMCID: PMC4103044

Abstract

BACKGROUND AND AIM: Patients with genotype 4 (G4) chronic hepatitis C (CHC) are considered a difficult to treat population, although current data on G4 treatment responsiveness and duration are controversial. Greece represents a country with an intermediate prevalence of G4 infections, offering an opportunity to compare treatment outcomes by genotype and to identify potential prognostic factors for sustained virologic response (SVR).

METHODS: All CHC patients from the HepNet.Greece, an ongoing nationwide cohort study on viral hepatitis, with known hepatitis C virus (HCV) genotype who received treatment with Peg-IFNa and ribavirin were analyzed.

RESULTS: From 4443 patients, 951 (61.7% males, 78.4% Greeks, median age 40.6 years, 10% cirrhosis) fulfilled the inclusion criteria. G4 was found in 125 (13.1%) patients. Genotype distribution was not significantly different between Greeks and immigrants. Patients with G4 had similar odds of SVR compared to G1 but significantly lower compared to G2/G3. Age, treatment discontinuation, presence of cirrhosis and previous history of HCV-treatment were associated with lower probabilities of SVR. Ethnicity did not affect SVR for all genotypes while response to treatment was similar between Greek and Egyptian patients groups (35.7% vs 40.9%, p=0.660%) with G4 infection. The relation between SVR and genotype did not substantially change after adjustment for age, gender, cirrhosis, treatment interruption and history of HCV-treatment.

CONCLUSIONS: The findings of this large cohort of CHC patients with a well balanced genotype distribution further supports the idea of considering G4 as a difficult to treat genotype. Further investigation is needed to identify genotype specific prognostic factors.

Keywords: HCV treatment; Viral hepatitis; interferon; pegylated-interferon

References

  1. J Viral Hepat. 2009 Mar;16(3):195-202 - PubMed
  2. J Viral Hepat. 2005 Sep;12(5):543-50 - PubMed
  3. Hippokratia. 2011 Jan;15(1):26-31 - PubMed
  4. J Clin Microbiol. 2005 Apr;43(4):1902-9 - PubMed
  5. Gut. 2005 Jun;54(6):858-66 - PubMed
  6. Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S97-S101 - PubMed
  7. Hepatology. 2009 Apr;49(4):1335-74 - PubMed
  8. Ann Intern Med. 2004 Mar 2;140(5):346-55 - PubMed
  9. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  10. J Infect Dis. 2000 Sep;182(3):698-707 - PubMed
  11. Hepatology. 2013 Apr;57(4):1333-42 - PubMed
  12. Gastroenterology. 2010 Jan;138(1):108-15 - PubMed
  13. Aliment Pharmacol Ther. 2009 May 15;29(10):1121-30 - PubMed
  14. Hepatology. 2003 Aug;38(2):518-26 - PubMed
  15. World J Gastroenterol. 2012 Dec 21;18(47):7003-8 - PubMed
  16. Am J Gastroenterol. 2005 Nov;100(11):2447-52 - PubMed
  17. J Viral Hepat. 2006 Jan;13(1):19-27 - PubMed
  18. Am J Gastroenterol. 2004 Sep;99(9):1733-7 - PubMed
  19. J Viral Hepat. 2005 Sep;12(5):551-7 - PubMed
  20. Hepatology. 2012 Feb;55(2):336-42 - PubMed
  21. J Hepatol. 2011 Jun;54(6):1250-62 - PubMed
  22. Hepatology. 2007 Dec;46(6):1732-40 - PubMed
  23. J Med Virol. 2012 Aug;84(8):1217-23 - PubMed
  24. Gut. 2012 May;61 Suppl 1:i36-46 - PubMed
  25. J Hepatol. 2012 Mar;56(3):527-32 - PubMed
  26. J Viral Hepat. 2007 Jul;14(7):460-7 - PubMed
  27. Radiology. 2003 Apr;227(1):89-94 - PubMed
  28. Hepatology. 2005 Oct;42(4):962-73 - PubMed
  29. Liver Int. 2010 Mar;30(3):342-55 - PubMed
  30. Gastroenterology. 2010 Jan;138(1):116-22 - PubMed
  31. Lancet Infect Dis. 2005 Sep;5(9):558-67 - PubMed
  32. N Engl J Med. 2002 Sep 26;347(13):975-82 - PubMed
  33. Gut. 2009 Dec;58(12):1662-9 - PubMed

Publication Types